PATIENTS WITH ENTHESITIS ACHIEVED RESOLUTION1*
Sustained resolution of preexisting enthesitis up to 3 years1,a
aPALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.
Patients treated with OTEZLA 30 mg BID achieved
significantly greater improvement vs placebo in MASES (enthesitis)
score (mean change of -1.3 vs 0.9, P = 0.0194) at week 241†
*Pooled patient data from PALACE 1-3; includes all randomized patients with preexisting enthesopathy (baseline MASES score >0; n = 945). Resolution was defined as a MASES score of 0.
†LOCF; for patients who qualified for early escape at week 16, the week 16 value was carried forward.
BID, twice daily; LOCF, last observation carried forward; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
PATIENTS WITH ENTHESITIS ACHIEVED RESOLUTION IN A REAL-WORLD SETTING2*
Resolution of preexisting enthesitis at months 1 and 42,a
aLAPIS-PsA study, interim analysis at 4 months. Data as observed among patients with value available at specified time point.
In a real-world setting, OTEZLA led to complete resolution of enthesitis2†
*Among patients with an LEI >0 at baseline (n = 49/111, 44.5%).
†Defined as LEI = 0.
LAPIS-PsA, Study of Apremilast Use in Patients with Psoriatic Arthritic in Practice Conditions; LEI, Leeds Enthesitis Index.
- Gladman DD, et al. Apremilast treatment and long-term (up to 156 weeks) improvements in dactylitis and enthesitis in patients with psoriatic arthritis: analysis of a large database of the phase III clinical development program. Ann Rheum Dis. 2017;76 (suppl 2): Abstract SAT0448.
- Wollenhaupt J, Vollmer M, Berger S, et al. Real-world insights on apremilast treatment in psoriatic arthritis patients: interim analysis of the multicenter LAPIS-PsA study. Presented at: the 45th Congress of the German Society of Rheumatology (DGRh); 6-9 September 2017; Stuttgart, Germany.